Prostatism

02/01/1996 - "Terazosin given once daily in a dose ranging from 2 to 10 mg in community-based urology practices under conditions simulating usual care is effective in reducing the symptoms, perception of bother, and the impairment of QQL due to urinary symptoms in men with moderate to severe symptoms of prostatism. "
03/01/1996 - "Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms."
07/01/1995 - "Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms."
07/01/1995 - "Our study demonstrates that terazosin is not effective for the treatment of prostatism-like symptoms in aging women."
03/01/1997 - "To determine if men with normal peak urinary flow rates (PFR) and prostatism respond to terazosin. "

01/01/1986 - "The alpha-adrenergic blocker phenoxybenzamine has been shown to be useful in the treatment of prostatism. "
10/01/1987 - "[A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism]."
11/01/1987 - "[Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination]."

01/01/1992 - "In the relief of uncomplicated prostatism in youthful patients, TUDP compares favorably with other treatment alternatives."
01/01/1992 - "Forty-three youthful patients with uncomplicated prostatism were prospectively evaluated to test the safety and efficacy of transurethral balloon dilation (TUDP). "
11/01/1990 - "A prospective noncontrolled study of the safety and potential efficacy of transurethral balloon catheter dilation of the prostate (TUDP) in the treatment of benign prostatic hyperplasia (BPH) was performed in 73 subjects with moderate to severe symptoms and signs of prostatism who were selected on the basis of a quantitative symptom score (SS), uroflowmetry measurements, and residual urine volume. "

10/01/1987 - "A double-blind placebo-controlled study of bunazosin for the treatment of symptomatic prostatism is reported, incorporating urologic departments of 25 hospitals. "
10/01/1987 - "[A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism]."
11/01/1987 - "[Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination]."

01/01/2001 - "The present study evaluates the efficacy of alfuzosin in a group of the patients with prostatism. "
01/01/2001 - "The efficacy of alfuzosin treatment in patients with prostatism."

09/01/1989 - "We conclude that leuprolide treatment of men with benign prostatic hypertrophy results in shrinkage of prostatic size and concomitant improvement in the obstructive symptoms of prostatism. "
09/01/1991 - "The average prostatic size (transrectal ultrasound), serum prostate specific antigen (PSA) levels and symptoms of prostatism were dramatically decreased with leuprolide alone. "

09/01/2008 - "After the 3-month treatment, no significant change was found in the patients' general condition, peripheral blood picture, liver and kidney function and sex hormones, while the symptoms of prostatism and urosis were markedly improved (P<0.01), and the volume of residue urine in the urinary bladder was obviously reduced. "

01/01/1997 - "Prazosin allowed the catheters to be removed, improved the symptoms of prostatism and/or controlled high blood pressure in seven, five and nine patients in each group, respectively. "

01/01/1986 - "The alpha-adrenergic blocker phenoxybenzamine has been shown to be useful in the treatment of prostatism. "

06/01/1995 - "All 3 patients had prostatism at presentation that caused renal failure in 2. After treatment with doxorubicin-based combination chemotherapy appropriate for the stage and the specific histological subtype, all 3 patients achieved a complete remission and remained free of disease after a minimum followup of 3 years. "

01/01/1994 - "Men presenting with symptoms of prostatism may have bladder outflow obstruction, detrusor instability or weak bladder contraction leading to low pressure/low flow voiding so it is perhaps not surprising that only 75% of men selected for TURP purely on the basis of symptoms have a good outcome. "
03/01/1990 - "The objective of this study was to determine the efficacy of transurethral prostatectomy in men with moderate symptoms of prostatism. "
01/01/1992 - "In a prospective, randomized study 60 patients with prostatism caused by small prostate glands (estimated weight < 20 g) had either transurethral prostatectomy (TURP, n = 31) or transurethral incision of the prostate (TUI, n = 29). "
01/01/1987 - "In a prospective, randomized study 21 patients with prostatism caused by small prostates (estimated weight less than 20 gram) had a transurethral prostatectomy (TURP), and 17 patients a transurethral incision of the prostate (TUI). "
11/01/2003 - "From January 2000 through December 2001, we randomized 128 BPH patients aged 55 to 74 years (average 61.4 +/- 2.7 years), all complaining of symptoms for prostatism for 1 to 14 years (average 4.5 +/- 1.5 years), to either transurethral rotoresection (TURotor; N = 58) or TURP (N = 70). "

05/01/1994 - "The patients, three men and one woman, aged 50-74 years, presented clinically with gross haematuria and irritative mictional syndrome; their background was prostatism with in-dwelling vesical catheter and repeat urinary infections. "
05/01/1980 - "With continued improvement in therapy for hematologic tumors and the improvement in survival, catheter drainage with its concomitant chance for sepsis is not a viable alternative to surgical therapy for prostatism."
01/01/2003 - "Pathogenetic aspects concerning bacterial virulence as well as host factors in susceptibility to UTI as urinary tract obstruction, vesicoureteral reflux, indwelling bladder catheters, pregnancy, diabetes mellitus, sexual activity, contraceptive methods, prostatism, menopause, advanced age and renal transplantation are discussed. "
06/26/1987 - "Complications included benign prostatic hypertrophy in 13 patients; prostatic cancer in four; urethral stricture in four; quadriplegia/paraplegia with indwelling urinary catheter in four; prostatism in three; and other conditions commonly recognized as altering the response to antibiotic treatment. "
12/01/1992 - "The prevalence of 1 or more symptoms of prostatism (hesitancy, straining, weak stream, intermittency or use of a catheter) among men who never had prostatic surgery is 35%. "

09/01/1998 - "Numerous published studies have shown that this laser procedure safely and effectively decreases symptoms of prostatism, increases the urinary flow rate, and reduces the volume of the prostate. "
01/01/1996 - "Although laser prostatectomy has become an accepted technique for the treatment of obstructive prostatism, considerable debate remains about which laser prostatectomy method to use in various treatment situations. "
02/01/1996 - "Two patients with this complication presented with symptoms of prostatism that were relieved by laser resection of the aberrant tissue."
07/01/1995 - "Early results with minimally invasive treatments such as laser prostatectomies, hyperthermia, and ultrasonic and radiofrequency ablation appear encouraging for those with moderate symptoms of prostatism. "
12/01/1995 - "Our main findings were that patients undergoing laser prostatectomy using the coagulation technique (visual laser ablation of the prostate) had higher reoperation rates (16% versus 0%, p = 0.0199) and were 4 times more likely to have prolonged postoperative urinary retention (25% versus 6.3%, p = 0.0389), evaporation and coagulation were effective at relieving symptoms of prostatism with significant improvement in American Urological Association symptom scores and post-void residual urine volumes compared to baseline, improvement in peak flow rates was significantly greater in patients undergoing evaporation at 1, 3, 6 and 12 months (p < 0.001) compared to coagulation, and a significantly greater amount of laser energy was required to evaporate a unit volume of prostate tissue compared to coagulation (2,251 J./cc versus 1,036 J./cc, p < 0.03). "

11/01/1996 - "Twenty patients with prostatism and a prostatic volume of 30-71 cm3 underwent MR examination before, the day after, and 6 months after treatment. "
04/01/1995 - "To study the evolving prostatic aperture created by visual laser ablation (VLAP), we performed 38 video-endoscopies in 24 men with prostatism at various intervals 2 weeks to 1 year after treatment. "
01/01/1995 - "The curvature of the urethral resistance relation was estimated in 21 normal men, in 32 prostatism patients, in 60 men with a diagnosis of benign prostatic hypertrophy (BPH) and obstruction, and in 55 men after treatment of BPH. "
06/01/1995 - "All 3 patients had prostatism at presentation that caused renal failure in 2. After treatment with doxorubicin-based combination chemotherapy appropriate for the stage and the specific histological subtype, all 3 patients achieved a complete remission and remained free of disease after a minimum followup of 3 years. "

04/01/1995 - "To study the evolving prostatic aperture created by visual laser ablation (VLAP), we performed 38 video-endoscopies in 24 men with prostatism at various intervals 2 weeks to 1 year after treatment. "
07/01/1993 - "Visual laser ablation of the prostate (VLAP) was evaluated by serial video-endoscopy and six months of clinical correlation in 7 men suffering from advanced prostatism and urinary retention. "
12/01/1995 - "Our main findings were that patients undergoing laser prostatectomy using the coagulation technique (visual laser ablation of the prostate) had higher reoperation rates (16% versus 0%, p = 0.0199) and were 4 times more likely to have prolonged postoperative urinary retention (25% versus 6.3%, p = 0.0389), evaporation and coagulation were effective at relieving symptoms of prostatism with significant improvement in American Urological Association symptom scores and post-void residual urine volumes compared to baseline, improvement in peak flow rates was significantly greater in patients undergoing evaporation at 1, 3, 6 and 12 months (p < 0.001) compared to coagulation, and a significantly greater amount of laser energy was required to evaporate a unit volume of prostate tissue compared to coagulation (2,251 J./cc versus 1,036 J./cc, p < 0.03). "